Biomm S.A.

São Paulo Stock Exchange BIOM3.SA

Biomm S.A. Net Income Margin for the year ending December 31, 2023: -68.65%

Biomm S.A. Net Income Margin is -68.65% for the year ending December 31, 2023, a 22.16% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Biomm S.A. Net Income Margin for the year ending December 31, 2022 was -88.19%, a -17.67% change year over year.
Biomm S.A. Net Income Margin for the year ending December 31, 2021 was -74.95%, a 37.87% change year over year.
Biomm S.A. Net Income Margin for the year ending December 31, 2020 was -120.62%, a 80.67% change year over year.
Biomm S.A. Net Income Margin for the year ending December 31, 2019 was -624.02%, a 77.04% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

São Paulo Stock Exchange: BIOM3.SA

Biomm S.A.

CEO	Mr. Heraldo Carvalho Marchezini
IPO Date	Jan. 11, 2000
Location	Brazil
Headquarters	Rua dos Pinheiros, 610
Employees	130
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care Pet Food

Description

Biomm S.A. operates as a biotechnology company in Brazil. It offers AFREZZA, a human insulin inhalation powder; CONFORT CARE, a moisturizing foot cream; GLARGILIN, a glargine insulin; and HERZUMA, a trastuzumab. Biomm S.A. was founded in 2001 and is based in São Paulo, Brazil.

Key trends

Past 5 years